Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9QF65)

• Drug Name: GR-MD-02 Drug Info
• Synonyms: Belapectin

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Phase 2	[1]
Melanoma	2C30	Phase 2	[2]
Plaque psoriasis	EA90.0	Phase 2	[3]
Non-alcoholic steatohepatitis	DB92.1	Phase 1	[4]

• Cross-matching ID: TTD Drug ID: DM9QF65

Molecule-Related Drug Atlas

Drug(s) Targeting Galectin-3 (LGALS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GB0139	DMA8KQR	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[6]
GB0139	DMA8KQR	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[7]
PFFFFF	DM9AZKE	Discovery agent	N.A.	Investigative	[8]
2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide	DM592YS	Discovery agent	N.A.	Investigative	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Galectin-3 (LGALS3)	TTFPQV7	LEG3_HUMAN	Inhibitor	[5]

References

• [1] ClinicalTrials.gov (NCT02462967) Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT02421094) Clinical Study for Non-Invasive Imaging Methods for GR-MD-02 for Treatment of Liver Fibrosis. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT01899859) Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. U.S. National Institutes of Health.
• [5] Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481.
• [6] An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE). Am J Respir Crit Care Med. 2023 Jan 15;207(2):138-149.
• [7] Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation. Front Pharmacol. 2022 Aug 8;13:949264.
• [8] Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. Bioorg Med Chem Lett. 2007 Feb 1;17(3):793-8.
• [9] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.